Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP002014) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
DARPin MP0274
|
|||||
| Synonyms |
MP-0274; SPA-28; CME-114; CME-115; CME-118; CME-119; DARPins (cancer), Molecular PartnersOncodesign
|
|||||
| Thermal Denaturation TEMP | 90 ℃ | |||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Expression System | Escherichia coli | |||||
| Selection Method | Phage display and Ribosome display | |||||
| Highest Status | Phase I | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS027 | [1] , [2] , [3] | ||||
| Scaffold Name | DARPin | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Alpha-Helices + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Receptor tyrosine-protein kinase erbB-2 | Antagonist | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | N.A. | Molecular Partners; Allergan; Oncodesign Biotechnology | [1] , [2] , [3] | |
| Epidermal growth factor receptor | Antagonist | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | N.A. | Molecular Partners; Allergan | [1] , [2] , [3] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03084926 | Click to show the Detail | |||||
| Indication | Advanced HER2-positive Solid?Tumor | |||||
| Phase | Phase I | |||||
| Title | A Phase I, First-in-human, Single-arm, Multi-center, Open-label, Repeated-Dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors | |||||
| Status | Active, not recruiting | |||||
| Sponsor | Molecular Partners | |||||